Robert Bitterman Biography and Net Worth

President & Chief Executive Officer of Phio Pharmaceuticals


Robert J. Bitterman has served as a member and the Chair of the Board since 2012 and as our President and Chief Executive Officer since February 2023. Mr. Bitterman served as the Interim Executive Chair of the Company from September 2022 to February 2023 until his appointment as President and Chief Executive Officer. Mr. Bitterman served as the President and Chief Executive Officer of Cutanea Life Sciences, Inc., a private company he founded in 2005 that focused on developing innovative technologies to treat diseases and disorders of the skin and subcutaneous tissue, until its acquisition by Biofrontera, Inc., USA in March 2019. Since leaving Cutanea, Mr. Bitterman was retired until commencing the Interim Executive Chair role with the Company in September 2022. Prior to his role at Cutanea Life Sciences, Inc., Mr. Bitterman also held the position of President and Chief Executive Officer of Isolagen, Inc., President and General Manager of Dermik Laboratories and various positions of increasing responsibility in financial and commercial capacities within Aventis S.A. Mr. Bitterman holds an A.B. degree in Economics from The College of the Holy Cross and a Master of Business Administration degree from Boston University. He also holds a Doctor of Humane Letters (Honoris Causa) from the New York College of Podiatric Medicine.

What is Robert J. Bitterman's net worth?

The estimated net worth of Robert J. Bitterman is at least $361.95 thousand as of September 22nd, 2026. Mr. Bitterman owns 364,871 shares of Phio Pharmaceuticals stock worth more than $361,952 as of October 6th. This net worth estimate does not reflect any other investments that Mr. Bitterman may own. Learn More about Robert J. Bitterman's net worth.

How do I contact Robert J. Bitterman?

The corporate mailing address for Mr. Bitterman and other Phio Pharmaceuticals executives is 411 Swedeland Road, Suite 23-1080, King OF Prussia, PA, 19406. Phio Pharmaceuticals can also be reached via phone at (508) 767-3861 and via email at [email protected]. Learn More on Robert J. Bitterman's contact information.

Has Robert J. Bitterman been buying or selling shares of Phio Pharmaceuticals?

Robert J. Bitterman has not been actively trading shares of Phio Pharmaceuticals over the course of the past ninety days. Most recently, on Tuesday, September 22nd, Robert J. Bitterman bought 2,000 shares of Phio Pharmaceuticals stock. The stock was acquired at an average cost of $1.03 per share, with a total value of $2,060.00. Following the completion of the transaction, the chief executive officer now directly owns 364,871 shares of the company's stock, valued at $375,817.13. Learn More on Robert J. Bitterman's trading history.

Who are Phio Pharmaceuticals' active insiders?

Phio Pharmaceuticals' insider roster includes Robert Bitterman (President & Chief Executive Officer), Patricia Bradford (Director), and Gerrit Dispersyn (CEO). Learn More on Phio Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Phio Pharmaceuticals?

During the last year, Phio Pharmaceuticals insiders bought shares 8 times. They purchased a total of 53,500 shares worth more than $57,925.00. The most recent insider tranaction occured on September, 28th when Director Ronald Todd Plott bought 5,000 shares worth more than $5,150.00. Insiders at Phio Pharmaceuticals own 3.5% of the company. Learn More about insider trades at Phio Pharmaceuticals.

Information on this page was last updated on 9/28/2026.

Robert J. Bitterman Insider Trading History at Phio Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/22/2026Buy2,000$1.03$2,060.00364,871View SEC Filing Icon  
6/26/2026Buy10,000$0.99$9,900.00421,421View SEC Filing Icon  
12/23/2025Buy5,000$1.02$5,100.00286,421View SEC Filing Icon  
11/21/2025Buy5,000$1.14$5,700.00281,421View SEC Filing Icon  
11/18/2025Buy5,000$1.27$6,350.00276,421View SEC Filing Icon  
6/10/2025Buy2,000$2.42$4,840.0027,149View SEC Filing Icon  
6/9/2025Buy1,500$2.75$4,125.0025,149View SEC Filing Icon  
5/22/2025Buy1,200$1.78$2,136.0023,649View SEC Filing Icon  
5/21/2025Buy3,000$1.77$5,310.0022,449View SEC Filing Icon  
6/6/2024Buy111$6.75$749.252,221View SEC Filing Icon  
2/26/2024Buy277$8.19$2,268.632,110View SEC Filing Icon  
6/30/2023Buy111$25.92$2,877.122,023View SEC Filing Icon  
12/14/2022Buy222$3.51$779.228,282View SEC Filing Icon  
12/7/2022Buy222$3.51$779.228,060View SEC Filing Icon  
11/29/2022Buy23$3.60$82.807,615View SEC Filing Icon  
11/25/2022Buy277$3.78$1,047.067,591View SEC Filing Icon  
11/16/2022Buy0$15,750.00$0.00View SEC Filing Icon  
See Full Table

Robert J. Bitterman Buying and Selling Activity at Phio Pharmaceuticals

This chart shows Robert J. Bitterman's buying and selling at Phio Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Phio Pharmaceuticals Company Overview

Phio Pharmaceuticals logo
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
Read More

Today's Range

Now: $0.99
Low: $0.97
High: $1.02

50 Day Range

MA: $1.06
Low: $0.98
High: $1.21

2 Week Range

Now: $0.99
Low: $0.81
High: $4.19

Volume

131,685 shs

Average Volume

1,478,603 shs

Market Capitalization

$11.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84